Pliant Therapeutics, Inc.
South San Francisco, USA
|
Pliant Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. The company's lead product candidate, bexotegrast (PLN-74809), is an oral, small molecule, dual selective inhibitor of αvß6 and αvß1 integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. The company has also developed PLN-1474, a small...